Aconitum

PMDA Updates

August, 2017

News

1. CVIT 2017 HBD Town Hall Meeting

On July 8, Harmonization By Doing (HBD) Town Hall Meeting was held in Kyoto in conjunction with the 26th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT 2017), where Dr. Yuka Suzuki, International Coordination Officer for Medical Devices and five staff members from PMDA participated. In the session entitled "CVIT 2017 THM (Japan-US Synergy) ~ Lead the World in Cardiovascular Therapy by Transmitting Higher Quality Evidences from Japan! ~", active presentations and discussions were held by participants from government, industry, and academia of Japan and the U.S. including U.S. FDA. The topics of the session were ① introduction of activities of HBD promoting global clinical trials, ② efforts to transmit high quality evidences from Japan, ③ clinical study results on the latest technology (bioresorbable stents and drug-coated balloon catheter for arteries of lower extremities) and an appropriate patient selection and an appropriate use of technology based on the results, and ④ AI, which has been actively developed, and its application to healthcare – the current trend and future possibility, and regulatory and review principles. Each session had an audience of more than 100 people, and a high level of interest was shown by the participants towards HBD activities and the latest technology.

The next HBD Town Hall Meeting will be held on September 11, 2017 in Las Vegas at Vascular Interventional Advances.

2. The 8th International Meeting of World Pharmacopoeias /The 9th Annual Meeting of Brazilian Pharmacopoeia

From July 11 to 12, the 8th International Meeting of World Pharmacopoeias was held in Brasilia, Brazil in which Dr. Haruhiro Okuda, Deputy Director-General, National Institute of Health Sciences (NIHS) as well as Mr. Naoyuki Yasuda, Office Director, Office of International Programs, and one staff member from Office of Standards and Guidelines Development, PMDA participated as the representatives of Japanese Pharmacopoeia (JP). The representatives of JP served as co-chairs again like the previous Tokyo meeting last September, and moderated the meeting. At this 8th International Meeting, final drafts of the additional chapters to the Good Pharmacopoeia Practices (GPhP) on Compounded Preparations, Herbal Medicines and Glossary were agreed, and will be finalized by the WHO Expert Committee on Specifications for Pharmaceutical Preparations this October. From July 13 to 14, the 9th Annual Meeting of Brazilian Pharmacopoeia was held, where the background and updates of each Pharmacopoeia including JP were explained.

The 9th International Meeting of World Pharmacopoeias will be held in April 2018 in Vietnam. The framework of the International Meeting of World Pharmacopoeias will provide an opportunity to exchange opinions on new items for discussion and to discuss future collaboration.

3. PMDA-ATC GMP Inspection Seminar 2017

From July 31 to August 4, PMDA held a seminar entitled "PMDA-ATC GMP Inspection Seminar 2017" in Yamaguchi prefecture, which was facilitated with the support of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). This seminar focusing on GMP was designed for GMP inspectors from oversea regulatory authorities, and participated by 13 regulators from Azerbaijan, Bangladesh, Hong Kong, Indonesia, Israel, Malaysia, Mexico, Myanmar, Russia, Singapore, South Africa, Thailand and Vietnam. In the seminar, lectures were delivered by PMDA staff and a PIC/S instructor on the topics including risk-based inspection planning and utilization of a site master file.

Lecture scene

The seminar also included group discussions and a mock inspection with the cooperation of an actual manufacturing site recommended by Japan Pharmaceutical Manufacturers Association (JPMA), and the participants had active discussions throughout the seminar.

Please refer to the following web site for the details of PMDA-ATC GMP Inspection Seminar 2017.

http://www.pmda.go.jp/english/symposia/0107.html

4. Call for application to the Summit of Heads of Medicines Regulatory Agencies Symposium starts

From October 23 to October 26, 2017, the international Summit of Heads of Medicines Regulatory Agencies and meeting of the International Coalition of Medicines Regulatory Authorities (ICMRA) will convene for the first time in Japan, at the Kyoto International Conference Center. This Summit will bring together regulatory authorities from more than 30 countries and regions around the world, including the United States, Europe, China, Brazil, and Japan. A main topic will be innovation in pharmaceuticals, medical devices, and regenerative medicine. Participants will exchange viewpoints on a variety of topics including future of relevant regulation, review processes, postmarketing surveillance, stable product supply, and risk management.

The 12th Summit and ICMRA meeting are not open to the public, but following completion of the closed meeting, on October 27, a one-day symposium will be offered to provide an early report of the results of the Summit. In addition to providing a "flash report" about the results of the Summit/ICMRA, representatives from a variety of countries and industries will discuss innovative technological developments and their practical applications, both current status and future expectations, and will discuss how the various national regulatory authorities address technological development and what challenges can be expected. There will also be a not-to-be missed presentation by Professor Shinya Yamanaka, Nobel laureate. The executive committee looks forward to seeing broad participation in this truly unique opportunity.

Please refer to the following web site for the details of the symposium and its on-line Registration.

http://www.c-linkage.co.jp/12th-summit-symposium/en/

5. Call for application to PMDA-ATC Medical Devices Seminar 2017 starts

PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) will hold a seminar entitled "PMDA-ATC Medical Devices Seminar 2017" from November 6 to 10, 2017. This seminar is designed for medical devices and in vitro diagnostics reviewers from overseas regulatory authorities. The seminar will cover wide range of topics including regulations, consultations (scientific advices), product reviews, and GCP/GLP/QMS. In addition, group discussions and a site visit to a training facility for proper use of advanced medical devices are planned as part of the seminar. The objective of the seminar is to provide the participants an opportunity to reflect on and enhance their regulatory systems.

Please refer to the following web site for the details of PMDA-ATC Medical Devices Seminar 2017.

http://www.pmda.go.jp/english/symposia/0110.html

6. Call for application to PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand starts

PMDA-ATC will hold the "PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand" from December 12 to 15. This seminar is designed for new drug application reviewers from overseas regulatory authorities. The objective of the seminar is to provide the participants with opportunities to acquire knowledge and perspectives on a wide range of topics including clinical trials, product application review, GCP/GLP, and post-marketing safety measures through lectures and case studies, and consequently apply them to enhance the regulatory system in the participants' own country or region.

Please refer to the following web site for the details of PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand.

http://www.pmda.go.jp/english/symposia/0111.html

English translations of review reports

The followings are current information about English version of review reports on PMDA web site.

Pharmaceuticals

http://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html

Brand Name	Generic Name	Posting date
Lumicef	brodalumab (genetical recombination)	July 18
Mekinist	trametinib dimethyl sulfoxide	July 28
Halaven [Initial Approval]	eribulin mesilate	July 28
Halaven [Partial Change Approval]	eribulin mesilate	July 28
Kanuma	sebelipase alfa (genetical recombination)	July 31

Safety Information

Pharmaceuticals and Medical Devices Safety Information No. 345, August 1, 2017

1. Summary of Guidance for Adverse Drug Reaction Reporting by Medical and Pharmaceutical Providers
2. Important Safety Information
   (1) Loxoprofen sodium hydrate (dermatologic preparation)
   (2) Fluconazole, Fosfluconazole
   (3) Nivolumab (genetical recombination)
3. Revision of Precautions (No. 286)
   Loxoprofen sodium hydrate (dermatologic preparation) (and 16 others)
4. List of Products Subject to Early Post-marketing Phase Vigilance
   (Posted on August 1, 2017)

http://www.pmda.go.jp/english/safety/info-services/drugs/medical-safety-information/0015.html

Pharmaceuticals Revisions of PRECAUTIONS, August 3, 2017

- Riociguat
- Warfarin potassium
- Azithromycin hydrate
- Laninamivir octanoate hydrate

http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0005.html

Risk Information which some safety measures might be taken (August 18, 2017)

- Dabigatran etexilate methanesulfonate
- Palivizumab (genetical recombination)
- Interferon beta

http://www.pmda.go.jp/english/safety/info-services/drugs/risk-communications/0001.html

Events

Conferences/Meetings PMDA hosts or participates in:

Date	Title	Location
September 10-12	RAPS (Regulatory Affairs Professional Society) Annual Conference	Washington, D.C.
September 11-12	PIC/S (Pharmaceutical Inspection Cooperation Scheme) Committee	Taipei
September 17-18	GCRSR/GSRS	Brasilia
September 19-21	12th IMDRF Management Committee Meeting	Ottawa
October 9-10	CoRE Advisory Board Meeting	Singapore
October 23-26	12th International Summit of Heads of Medicines Regulatory Agencies / International Coalition of Medicines Regulatory Authorities (ICMRA)	Kyoto

Reports from overseas

Our officers deliver lively reports of their activities at their stationed overseas authorities.

International collaboration in the area of GCP

International harmonization activities relating to GCP have been promoted in particular through the adoption of relevant guidelines under ICH, supported by regulators and industry from Japan and EU. These ICH GCP guidelines have been fully implemented by both Japan and EU. Both PMDA and EMA also provide opportunities for non-ICH international regulators to receive training and exchange opinions on the area of GCP, which has contributed to the promotion of harmonization/cooperation in GCP field.

Furthermore, EMA and FDA have conducted a collaborative activity, named GCP Initiative. In the Initiative, under their confidentiality arrangement, they are advancing collaborations such as routine exchanges of information on GCP, sharing of procedures, skills and knowledge of GCP inspections and cooperation in the conduct of inspections.

In Japan, numbers of notifications of multi-regional clinical trials as well as new drug pre-market review applications that have also been submitted in EU and/or USA at the similar time are growing. This is why it has become more important for PMDA to aim at more effective implementation of GCP system by being involved in such activities as GCP initiative and getting opportunities of further information exchanges and discussions.

Mr. Hideyuki Kondo
PMDA's International Liaison Officer stationed at EMA in the United Kingdom

Modernization of USP Packaging Standards for Glass and Elastomeric Components

The modernization of USP (United States Pharmacopeia) packaging standards has been ongoing since 2015 [1), 2)]. On June 19-20, 2017, USP conducted a workshop to discuss the modernization of its glass and elastomeric standards [3)]. During this workshop, USP Expert Committee members gave an overview, background and rationale for the proposed revision to the glass and elastomeric standard. There were also presentations on current U.S.

regulations related to pharmaceutical packaging and on analytical methods for determining packaging containers quality. Dr. Yukio Hiyama, a Japanese Pharmacopoeia (JP) Expert Committee member who works at the National Institute of Health Sciences (NIHS) attended the workshop, and gave a presentation on the packaging requirements in JP 17th Edition. During his presentation, he also outlined the pharmaceutical packaging chapter revisions in the first supplement to JP 17th Edition, including a new general information chapter for glass containers.

By attending this workshop, I was able to learn: ① the importance of the packaging system impacting on drug product quality and patient safety; ② majority of the particles that you find in a finished drug product comes from the packaging system and its assembly; ③ in the select of a packaging material/component one has to have a basic understanding of the component characteristics and the intended use of the component (e.g. oral product vs. injection) and: ④ the necessity to set the appropriate control specifications, based on information about the component and its manufacturing process.

The management of pharmaceutical packaging is important in order to assure product/packaging compatibility, quality and safety. Therefore, I will keep watching trends of technologies and regulations related to pharmaceutical packaging.

1) Comment Period Extended for Packaging General Chapters Appearing in Pharmacopeial Forum 43(3) http://www.uspnf.com/notices/comment-period-extended-packaging-general-chapters-appearing-pharmacopeial-forum-43-3
2) General Chapters: <659> Packaging and Storage Requirements, <661> Plastic Packaging Systems and Their Materials of Construction, <661.1>Plastic Materials of Construction, <661.2> Plastic Packaging Systems for Pharmaceutical Use http://www.uspnf.com/notices/general-chapters-plastic
3) USP Workshop on Modernization of USP Packaging Standards for Glass and Elastomeric Components http://www.usp.org/meetings-courses/workshops/modernization-usp-packaging-standards-glass-and-elastomeric-components

Dr. Yujiro Kameyama
PMDA's Liaison Officer stationed at USP in the U.S.A

Look back upon one year of the U.S.FDA dispatch

This is the final report of my U.S.FDA dispatch because I will finish my program in U.S.FDA at the end of August 2017. I would like to look back at major topics in U.S.FDA during my stay.

First, Dr. Robert Califf, the former commissioner of U.S.FDA, resigned in January 2017 as the new administration and Dr. Scott Gottlieb took over in May 2017. Commissioner Gottlieb announced new measures such as helping assess opioid drugs to deter abuse [1)], and improving patient access to prescription drug mainly focusing on generic drugs [2)]. These issues are currently serious problems in the United States, and U.S.FDA continues to make efforts to promote and protect the public health.

Second, there were some important dates in the area of data standards in 2016 – 2017 [3)]. Besides this data standards topic, U.S.FDA is trying to leverage Health IT to improve drug development such as utilization of electronic health record and to enhance access and usability of Risk Evaluation and Mitigation Strategy (REMS) in post-marketing safety [4)]. Plus, the scope of digital health in U.S.FDA includes wearable medical devices.

Third, from the viewpoint of clinical medicine, U.S.FDA revealed utilization of patient perspective to inform FDA's regulatory decision-making based on the 21st Century Cures Act started in January 2017 [5)]. The methodology of drug developments is expected to progress including Patient-Focused Drug Development Initiative that I reported in the previous PMDA Updates [6)].

Looking at these topics in U.S.FDA is a precious experience for me during this U.S.FDA dispatch. Finally, I deeply appreciate supports from all of the staff in the Office of Strategic Programs, U.S.FDA, and Advanced Review and Data Promotion Group, PMDA. I would like to enhance communications between U.S.FDA and PMDA based on my knowledge and experience I acquired from this U.S.FDA dispatch.

1) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562961.htm
2) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm564725.htm
3) PMDA Updates, March 2017. http://www.pmda.go.jp/files/000217413.pdf
4) http://www.pharmexec.com/leveraging-health-it-improve-drug-development
5) http://blogs.fda.gov/fdavoice/index.php/2017/07/how-fda-plans-to-help-consumers-capitalize-on-advances-in-science/
6) PMDA Updates, June 2017. http://www.pmda.go.jp/files/000218683.pdf

Dr. Ken Sakushima
Office of Strategic Programs, U.S. FDA in the U.S.A.